Pesquisa | BVS Doenças Infecciosas e Parasitárias

1.

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Martin, P; Jung, S-H; Pitcher, B; Bartlett, N L; Blum, K A; Shea, T; Hsi, E D; Ruan, J; Smith, S E; Leonard, J P; Cheson, B D.

Ann Oncol ; 28(11): 2806-2812, 2017 Nov 01.

Artigo em Inglês | MEDLINE | ID: mdl-28945884

2.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato, A R; Hill, B T; Lamanna, N; Barr, P M; Ujjani, C S; Brander, D M; Howlett, C; Skarbnik, A P; Cheson, B D; Zent, C S; Pu, J J; Kiselev, P; Foon, K; Lenhart, J; Henick Bachow, S; Winter, A M; Cruz, A-L; Claxton, D F; Goy, A; Daniel, C; Isaac, K; Kennard, K H; Timlin, C; Fanning, M; Gashonia, L; Yacur, M; Svoboda, J; Schuster, S J; Nabhan, C.

Ann Oncol ; 28(5): 1050-1056, 2017 05 01.

Artigo em Inglês | MEDLINE | ID: mdl-28453705

3.

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Hong, F; Habermann, T M; Gordon, L I; Hochster, H; Gascoyne, R D; Morrison, V A; Fisher, R I; Bartlett, N L; Stiff, P J; Cheson, B D; Crump, M; Horning, S J; Kahl, B S.

Ann Oncol ; 25(3): 669-674, 2014 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-24567515

4.

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Czuczman, M S; Leonard, J P; Jung, S; Johnson, J L; Hsi, E D; Byrd, J C; Cheson, B D.

Ann Oncol ; 29(11): 2271, 2018 11 01.

Artigo em Inglês | MEDLINE | ID: mdl-29390097

5.

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Czuczman, M S; Leonard, J P; Jung, S; Johnson, J L; Hsi, E D; Byrd, J C; Cheson, B D.

Ann Oncol ; 23(9): 2356-2362, 2012 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-22357442

6.

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Rosenwald, A; Alizadeh, A A; Widhopf, G; Simon, R; Davis, R E; Yu, X; Yang, L; Pickeral, O K; Rassenti, L Z; Powell, J; Botstein, D; Byrd, J C; Grever, M R; Cheson, B D; Chiorazzi, N; Wilson, W H; Kipps, T J; Brown, P O; Staudt, L M.

J Exp Med ; 194(11): 1639-47, 2001 Dec 03.

Artigo em Inglês | MEDLINE | ID: mdl-11733578

7.

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcÎ³RIIIa-158 V/F polymorphism.

Blum, K A; Jung, S-H; Johnson, J L; Lin, T S; Hsi, E D; Lucas, D M; Byrd, J C; Cheson, B D; Bartlett, N L.

Ann Oncol ; 21(11): 2246-2254, 2010 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-20423913

8.

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

Crump, M; Coiffier, B; Jacobsen, E D; Sun, L; Ricker, J L; Xie, H; Frankel, S R; Randolph, S S; Cheson, B D.

Ann Oncol ; 19(5): 964-9, 2008 May.

Artigo em Inglês | MEDLINE | ID: mdl-18296419

9.

The origin of the chemiluminescence of phagocytosing granulocytes.

Cheson, B D; Christensen, R L; Sperling, R; Kohler, B E; Babior, B M.

J Clin Invest ; 58(4): 789-96, 1976 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-965486

10.

Quality-of-life assessment in cancer treatment protocols: research issues in protocol development.

Gotay, C C; Korn, E L; McCabe, M S; Moore, T D; Cheson, B D.

J Natl Cancer Inst ; 84(8): 575-9, 1992 Apr 15.

Artigo em Inglês | MEDLINE | ID: mdl-1556768

11.

Cephalotaxine esters: antileukemic advance or therapeutic failure?

Grem, J L; Cheson, B D; King, S A; Leyland-Jones, B; Suffness, M.

J Natl Cancer Inst ; 80(14): 1095-103, 1988 Sep 21.

Artigo em Inglês | MEDLINE | ID: mdl-3045335

12.

Pentostatin in hairy cell leukemia: treatment by the special exception mechanism.

Grem, J L; King, S A; Cheson, B D; Leyland-Jones, B; Wittes, R E.

J Natl Cancer Inst ; 81(6): 448-53, 1989 Mar 15.

Artigo em Inglês | MEDLINE | ID: mdl-2783980

13.

Infectious and immunosuppressive complications of purine analog therapy.

Cheson, B D.

J Clin Oncol ; 13(9): 2431-48, 1995 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-7666104

14.

Interpretation of clinical trials in diffuse large-cell lymphoma.

Armitage, J O; Cheson, B D.

J Clin Oncol ; 6(8): 1335-47, 1988 Aug.

Artigo em Inglês | MEDLINE | ID: mdl-3045267

15.

Retinoids in cancer therapy.

Smith, M A; Parkinson, D R; Cheson, B D; Friedman, M A.

J Clin Oncol ; 10(5): 839-64, 1992 May.

Artigo em Inglês | MEDLINE | ID: mdl-1569455

16.

Neurotoxicity of purine analogs: a review.

Cheson, B D; Vena, D A; Foss, F M; Sorensen, J M.

J Clin Oncol ; 12(10): 2216-28, 1994 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-7931492

17.

The systemic administration of intravenous melphalan.

Sarosy, G; Leyland-Jones, B; Soochan, P; Cheson, B D.

J Clin Oncol ; 6(11): 1768-82, 1988 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-3054005

18.

Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.

Cheson, B D; Vena, D A; Barrett, J; Freidlin, B.

J Clin Oncol ; 17(8): 2454-60, 1999 Aug.

Artigo em Inglês | MEDLINE | ID: mdl-10561309

19.

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.

Cheson, B D; Jasperse, D M; Simon, R; Friedman, M A.

J Clin Oncol ; 4(12): 1857-64, 1986 Dec.

Artigo em Inglês | MEDLINE | ID: mdl-3537219

20.

Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.

Chun, H G; Leyland-Jones, B; Cheson, B D.

J Clin Oncol ; 9(1): 175-88, 1991 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-1702143

BVS Doenças Infecciosas e Parasitárias

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcÎ³RIIIa-158 V/F polymorphism.

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

The origin of the chemiluminescence of phagocytosing granulocytes.

Quality-of-life assessment in cancer treatment protocols: research issues in protocol development.

Cephalotaxine esters: antileukemic advance or therapeutic failure?

Pentostatin in hairy cell leukemia: treatment by the special exception mechanism.

Infectious and immunosuppressive complications of purine analog therapy.

Interpretation of clinical trials in diffuse large-cell lymphoma.

Retinoids in cancer therapy.

Neurotoxicity of purine analogs: a review.

The systemic administration of intravenous melphalan.

Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.

Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.